Hopes thin for future of Astra&#39;s blood drug
121380
THE future of AstraZenecaâs blood-thinning medicine, Exanta, was thrown into fresh doubt last night after Franceâs leading drugs regulator confirmed that it was reviewing the medicineâs approval status.
425170
Faced with weak development pipelines that are putting a drag on stock prices, drug manufacturers are retooling the decades-old system of clinical trials to make it faster and cheaper.
526962
As worries for its anemia drugs abate, investors will start to worry about Merck and Novartis.
455403
The biopharma announces a dramatic shift following the failure of its lead drug.
15055
AstraZeneca Plc (AZN) on Friday said US regulators did not approve its anti-clotting drug Exanta. The US Food and Drug Administration followed the advice of an advisory panel, which last
387905
The beleaguered drug giant&#39;s lowered forecast isn&#39;t as bad as Wall Street expected. But investors still await the long-term prognosis.
520589
Investors are discouraged after it releases the latest data for its top drug.
550692
NEW YORK - Today at the UBS Global Life Sciences Conference, AtheroGenics was met with pointed skepticism over trial results for its drug, AGI-1067.
462762
Biopure Corp. is running out of money -- again. Recent regulatory filings, including one yesterday, show the Cambridge blood-substitute developer seeking the financial flexibility it says it will need to keep operating after January. That's when it expects to use up the $7 million it raised through a stock sale in September.
115250
A high-dose regimen of Merck&#39;s cholesterol drug Zocor offered no conclusive benefits over a low-cholesterol diet and a lower dose of Zocor in preventing a recurrence of cardiac events
414602
Stock falls on news treatment failed a mid-stage trial, company will cease developing drug. NEW YORK  - AtheroGenics Inc.
226836
AstraZeneca Plc suffered its third setback in two months on Friday as lung cancer drug Iressa failed to help patients live longer
348531
That would be small consolation to pharma investors.
161495
Progress on its lead drug remains stalled.
310266
Trial results for a drug that controls bleeding include a favorable comparison with a similar product.
725261
There's encouraging news about an enzyme replacement drug.
268925
The British-Swedish drug company has a great quarter, but the future looks dimmer.